Skip to main content

Upper respiratory tract infections

SARS, influenza, RSV, common cold, …

2020-11-24 — 2026-04-07

quality 5

Wherein the Clinical Evidence for Several Antiviral Nasal Sprays Is Surveyed by Active Ingredient, and Intranasal Zinc Is Identified as Carrying a Risk of Permanent Anosmia.

branching
count data
DIY
fit
health
life
networks
stochastic processes
straya
tail risk
time series
Figure 1: Ah-choo!

Nothing too fancy here, but apparently I need a notebook to collect basic health and hygiene tips for respiratory viruses, because just grabbing random sprays off the shelf turns out to be unhelpful and possibly dangerous.

1 Epidemiology of

See also epidemiology, contact tracing.

2 Topical sprays

Various nasal sprays are used for colds and other viruses; some might affect COVID-19 or other respiratory viruses (Kramer et al. 2021; Fais et al. 2022; Friedland et al. 2022; Kozlov 2022; Little et al. 2024). The evidence varies by active ingredient — from well-replicated RCTs down to in vitro studies and from there down on to vibes. Regulatory status varies

2.1 Iota-carrageenan

Iota-carrageenan is a “sulphated polysaccharide” derived from red seaweed. It as been tested in several RCTs and reduces viral load which I believe means that if I use this stuff maybe I am healthier insofar as detecting fewer virions coming out of my schnozz indicates I am healthier. More importantly, shortens common cold duration (by ~1–2 days) (Figueroa et al. 2021; Hemilä and Chalker 2021), A re-analysis of two earlier placebo-controlled trials estimated it could approximately double the rate of recovery from coronavirus and influenza infections, maybe.

They claim its primary mode of action is as a physical barrier, coating viral particles and preventing them from binding to mucosal cells, which also conveniently lets them speed-run FDA approval as a medical device rather than a drug. The safety profile is good — adverse events in trials were comparable to placebo.

Availability: Carrageenan nasal sprays are widely available. In Australia, Flo Travel nasal spray contains iota-carrageenan. In Europe, products include Coldamaris (Austria/Germany), Algovir (Germany), and Betadine Cold Defence (various EU markets via Mundipharma). In the UK, products are available on Amazon. In the US, EPOTHEX and generic carrageenan sprays are sold on Amazon. The active ingredient is licensed as Carragelose® by Marinomed Biotech.

2.2 Nitric oxide nasal sprays

Nitric oxide (NO) is an endogenous antimicrobial molecule, i.e. one that our bodies produce already, which in principle might be great for controlling respiratory diseases (Wright, McGrowder, and Bryan 2025; Zhao et al. 2023; AbdelMassih et al. 2021).

SaNOtize developed a slow-release nitric oxide nasal spray that generates NO up the schnozz. Impressive clinical trials (Sanotize Research and Development corp. 2021; Winchester et al. 2021; Salman 2021) reported that it reduced SARS-CoV-2 viral RNA load by >95% within 24 hours and >99% within 72 hours, and faster symptom resolution compared to placebo. A 2026 in vitro study also demonstrated broad-spectrum virucidal activity against influenza A (H1N1, H3N2, H5N1), influenza B, rhinovirus, RSV, hMPV, and HPIV-3. That said, no serious adverse events were recorded across >1,000 patients in completed trials.

Availability: Sold as Enovid in Israel and Indonesia; as VirX in Thailand, Singapore, Hong Kong, South Africa, Malaysia, Cambodia, and Germany; and as FabiSpray (by prescription) in India. Not yet approved by the FDA or Health Canada, though the US launch under the NOWONDER brand (🚧TODO🚧 Is this for real?) was announced for 2025. In particular, not (formally) available in Australia. Available for international purchase through shop-enovid.com.

See Those Nerdy Girls:Does nitric oxide nasal spray (Enovid/VirX/FabiSpray) help prevent or treat COVID-19?.

2.3 Hypochlorous acid nasal sprays

Hypochlorous acid (HOCl) is the active antimicrobial species produced by neutrophils, so it’s biologically plausible as a topical treatment for respiratory infections. In vitro studies show activity against SARS-CoV-2, influenza, and other respiratory pathogens (Winter, Boecker, and Posch 2025).

The clinical evidence is not earth shattering, but HOCl has one decisive advantage: it is already approved as an antiseptic/wound care agent in several jurisdictions (US, EU), so HOCl-based products like Sentinox are available in those markets. The specific indication for respiratory viruses has not been formally approved anywhere AFAICS

Availability in Australia: Complicated. HOCl disinfectant products (e.g. Hydro-E) are TGA-approved for surface/hospital-grade disinfection, but no HOCl nasal spray appears to have TGA listing as a therapeutic product. Some imported products (e.g. Sinus Plumber) can be found on online marketplaces, but these are US-market products without TGA registration. May be worth checking a compounding pharmacy if you want something formulated for nasal use — HOCl itself is not a controlled substance.

2.4 Povidone-iodine (PVP‑I)

Povidone-iodine has well-established broad-spectrum virucidal properties — it is after all the basis of Betadine, which we squirt over every cut and graze over here.. At 0.5% concentration in nasal spray form, it is virucidal against SARS-CoV-2 in vitro (Pelletier et al. 2021; Friedland et al. 2022; Zarabanda et al. 2022). The key question is whether this translates to clinical benefit.

A Phase III RCT (n=260) by the manufacturer found that PVP-I nasal spray did not significantly beat saline on nasal symptom score, but the global severity score was borderline good, showing a near-significant 12.6% benefit (p=0.054) (Polasek and Friedland 2025). Post hoc subgroup analyses were better, but of course they always are.

Side effects seemed mild, but might be weird for for people with thyroid disorders, since it releases iodine.

Availability: The TGA declined to approve Nasodine nasal spray for the common cold in Australia, and manufacturer Firebrick Pharma withdrew its appeal in early 2024. Nasodine throat spray (1% PVP-I) received TGA listing in October 2025, but the nasal spray remains unavailable in Australia.

2.5 Zinc

Intranasal zinc not recommended (Hemilä and Chalker 2024; Hulisz 2004; Hunter et al. 2021; Ronald 2001). Oral zinc lozenges may modestly shorten cold duration (by ~2 days per Cochrane), but squirting a spray up the nose carry a risk of anosmia — permanent loss of smell (Jafek, Linschoten, and Murrow 2004), so they got an FDA advisory in 2009 and were withdrawn from the US market. Case reports describe a “zinc-induced anosmia syndrome” in which patients experience burning on application followed by immediate and sometimes irreversible loss of their ability to smell stuff. It seems that zinc can be toxic to local olfactory receptor neurons. Given that the therapeutic benefit is marginal and the potential harm is severe and irreversible, keep this away from your face holes.

Availability in Australia: most pharmacists.

3 Airborne transmission

Figure 2

There are probably several reasons we were slow to be careful about sharing the contents of our lungs with each other in the West. Here’s an interesting one: The 60-Year-Old Scientific Screwup That Helped Covid Kill documents the debate about which particle sizes can transmit viruses, and traces the lineage of cargo-cult science that helped those misunderstandings persist.

3.1 Protective masks

See hygienic masks for details on mask types and fit.

4 COVID-19

All my COVID-19 content is archived here.

5 Incoming

6 References

AbdelMassih, Hozaien, El Shershaby, et al. 2021. “The Potential Role of Inhaled Nitric Oxide for Postexposure Chemoprophylaxis of COVID-19.” Journal of Genetic Engineering and Biotechnology.
Adam. 2020. “Special Report: The Simulations Driving the World’s Response to COVID-19.” Nature.
Bazant, and Bush. 2021. “A Guideline to Limit Indoor Airborne Transmission of COVID-19.” Proceedings of the National Academy of Sciences.
Briggs, Goldstein, Kirwin, et al. 2021. “Estimating (Quality-Adjusted) Life-Year Losses Associated with Deaths: With Application to COVID-19.” Health Economics.
Burridge, Fan, Jones, et al. 2021. “Predictive and Retrospective Modelling of Airborne Infection Risk Using Monitored Carbon Dioxide.” Indoor and Built Environment.
Chavda, Baviskar, Vaghela, et al. 2023. “Nasal Sprays for Treating COVID-19: A Scientific Note.” Pharmacological Reports.
Cheung, Lee, Hui, et al. 2014. “Effect of pH on Fungal Growth: Problems with Using Vinegar (5% Acetic Acid) in Treating Superficial Fungal Infections.”
Cirillo, and Taleb. 2020. “Tail Risk of Contagious Diseases.” Nature Physics.
Cuschieri, Calleja, Devleesschauwer, et al. 2021. “Estimating the Direct Covid-19 Disability-Adjusted Life Years Impact on the Malta Population for the First Full Year.” BMC Public Health.
Dolan, and Kahneman. 2008. “Interpretations Of Utility And Their Implications For The Valuation Of Health*.” The Economic Journal.
Fais, Juskeviciene, Francardo, et al. 2022. “Drug-Free Nasal Spray as a Barrier Against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.” International Journal of Molecular Sciences.
Figueroa, Lombardo, Dogliotti, et al. 2021. “Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.” International Journal of General Medicine.
Friedland, Tucker, Goodall, et al. 2022. “In Vivo (Human) and in Vitro Inactivation of SARS-CoV-2 with 0.5% Povidone-Iodine Nasal Spray.” Australian Journal of Otolaryngology.
Hemilä, and Chalker. 2021. “Carrageenan Nasal Spray May Double the Rate of Recovery from Coronavirus and Influenza Virus Infections: Re‐analysis of Randomized Trial Data.” Pharmacology Research & Perspectives.
———. 2024. “Shortcomings in the Cochrane Review on Zinc for the Common Cold (2024).” Frontiers in Medicine.
Hulisz. 2004. “Efficacy of Zinc Against Common Cold Viruses: An Overview.” Journal of the American Pharmacists Association.
Hunter, Arentz, Goldenberg, et al. 2021. “Zinc for the Prevention or Treatment of Acute Viral Respiratory Tract Infections in Adults: A Rapid Systematic Review and Meta-Analysis of Randomised Controlled Trials.” BMJ Open.
Jafek, Linschoten, and Murrow. 2004. “Anosmia After Intranasal Zinc Gluconate Use.” American Journal of Rhinology.
Kimmitt, and Redway. 2016. “Evaluation of the Potential for Virus Dispersal During Hand Drying: A Comparison of Three Methods.” Journal of Applied Microbiology.
Kozlov. 2022. “Could a Nose Spray a Day Keep COVID Away?” Nature.
Kramer, Eggers, Hübner, et al. 2021. “Virucidal Gargling and Virucidal Nasal Spray.” GMS Hygiene and Infection Control.
Little, Vennik, Rumsby, et al. 2024. “Nasal Sprays and Behavioural Interventions Compared with Usual Care for Acute Respiratory Illness in Primary Care: A Randomised, Controlled, Open-Label, Parallel-Group Trial.” The Lancet Respiratory Medicine.
Noakes, and Sleigh. 2009. “Mathematical Models for Assessing the Role of Airflow on the Risk of Airborne Infection in Hospital Wards.” Journal of the Royal Society Interface.
Pelletier, Tessema, Frank, et al. 2021. “Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).” Ear, Nose & Throat Journal.
Piroth, Cottenet, Mariet, et al. 2021. “Comparison of the Characteristics, Morbidity, and Mortality of COVID-19 and Seasonal Influenza: A Nationwide, Population-Based Retrospective Cohort Study.” The Lancet Respiratory Medicine.
Polasek, and Friedland. 2025. “Povidone-Iodine Nasal Spray (Nasodine®) for the Common Cold: A Randomized, Controlled, Double-Blind, Phase III Clinical Trial.” Frontiers in Medicine.
Ronald. 2001. “Ineffectiveness of Intranasal Zinc Gluconate for Prevention of Experimental Rhinovirus Colds.” Clinical Infectious Diseases.
Salman. 2021. “A Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19.” Clinical trial registration NCT05012319.
Sanotize Research and Development corp. 2021. “Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection.” Clinical trial registration NCT04337918.
Sze To, and Chao. 2010. “Review and Comparison Between the Wells–Riley and Dose‐response Approaches to Risk Assessment of Infectious Respiratory Diseases.” Indoor Air.
Wang, Prather, Sznitman, et al. 2021. “Airborne Transmission of Respiratory Viruses.” Science.
Winchester, John, Jabbar, et al. 2021. “Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection.” The Journal of Infection.
Winter, Boecker, and Posch. 2025. “Hypochlorous Acid (HOCl) as a Promising Respiratory Antiseptic.” Viruses.
Wong, Kelly, Ip, et al. 2013. “Case Fatality Risk of Influenza A(H1N1pdm09): A Systematic Review.” Epidemiology (Cambridge, Mass.).
Wouterse, Ram, and van Baal. 2022. “Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands.” Value in Health.
Wright, McGrowder, and Bryan. 2025. “Nitric Oxide in the Treatment of COVID-19: Nasal Sprays, Inhalants and Nanoparticles.” Biochemistry Research International.
Zarabanda, Vukkadala, Phillips, et al. 2022. “The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.” The Laryngoscope.
Zhao, Li, Zhang, et al. 2023. “Inhaled Nitric Oxide: Can It Serve as a Savior for COVID-19 and Related Respiratory and Cardiovascular Diseases?” Frontiers in Microbiology.